uniQure (NASDAQ:QURE) Releases Quarterly Earnings Results, Misses Expectations By $0.90 EPS

uniQure (NASDAQ:QURE) issued its earnings results on Thursday. The biotechnology company reported ($1.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.90), Zacks reports. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%.

uniQure Stock Performance

QURE traded up $0.31 during trading on Thursday, hitting $11.98. 738,137 shares of the company traded hands, compared to its average volume of 1,002,023. uniQure has a one year low of $3.73 and a one year high of $19.18. The stock’s fifty day moving average is $15.19 and its 200 day moving average is $9.73. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The firm has a market cap of $583.70 million, a P/E ratio of -2.39 and a beta of 0.39.

Analyst Ratings Changes

A number of research analysts have weighed in on QURE shares. Mizuho raised their price objective on shares of uniQure from $7.00 to $20.00 and gave the company a “neutral” rating in a research note on Thursday, December 19th. The Goldman Sachs Group lifted their price target on uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a research note on Thursday, December 12th. Stifel Nicolaus increased their price objective on uniQure from $12.00 to $32.00 and gave the stock a “buy” rating in a research note on Monday, December 16th. HC Wainwright lifted their target price on uniQure from $25.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, January 27th. Finally, Wells Fargo & Company raised uniQure from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, uniQure has a consensus rating of “Moderate Buy” and a consensus target price of $40.00.

Insiders Place Their Bets

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of the business’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the sale, the chief executive officer now directly owns 597,915 shares in the company, valued at $4,562,091.45. The trade was a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 4.74% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.